Friday, April 26, 2024 4/26/2024

Magnetic Resonance (MR) Fingerprinting for Quantification of Pancreatic Tumor Microvasculature

Award Number: R01DK117459
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

PROJECT SUMMARY The overarching goal of this project is to develop, translate, and apply magnetic resonance fingerprinting (MRF), a novel, quantitatively robust magnetic resonance imaging (MRI) technique, for steady-state imaging of pancreatic ductal adenocarcinoma (PDAC) microvasculature using magnetic nanoparticles (MNP). MRF is a novel pattern matching based imaging method, which allows for simultaneous quantitative mapping of multiple parameters in a much shorter time than conventional imaging methods. Our experience in preclinical murine models of PDAC has revealed that MR imaging of ferumoxytol (an FDA-approved MNP) enables quantitative measurement of tumor microvasculature (e.g., vascular volume fraction (VVF), vessel size imaging (VSI) and vessel density index (VDI)). These measurements are all derived from changes in the quantitative MRI derived relaxation parameters, T2 and T2*. More importantly, we have shown that changes in these microvascular parameters can be a surrogate to therapeutic response following therapeutic manipulation of the tumor microenvironment through collagen disruption (e.g., angiotensin receptor blockade). Currently, MRF has not been optimized for abdominal imaging, nor is there a solution for T2* quantification. Our goal is to develop, translate, and apply MRF for improved and co-localized quantification of T2 and T2* in the human pancreas, prior to and following administration of MNP. The T2 and T2* values will then be used to quantify PDAC microvascularity and these results will be compared to histology. In order to complete this task, we have formed a multi-disciplinary team that includes expertise in MRI, quantitative imaging, surgical oncology, pathology, cancer biology, statistics, and pancreatic cancer. The team will conduct the following aims: 1) develop and optimize MR fingerprinting sequence for T1, T2 and T2* quantification in the pancreas; 2) validate T1, T2 and T2* MRF sequence in the pancreas of healthy volunteers; and 3) apply MRF T1, T2 and T2* sequences in patients with PDAC and correlate with pathology. An unmet need for imaging with high spatial resolution microvessel parameters following MNP (most notably, VSI) in pancreatic cancer is a technique that allows for simultaneous measures of T2 and T2*. We hypothesize that MRF, which is a quantitatively robust novel MR methodology, will be the most robust means of calculating T2 and T2* in the human pancreas following MNP, but secondary to its spiral technique, will provide these measures with a free breathing, highly reproducible and high image quality examination.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	OREGON HEALTH & SCIENCE UNIVERSITY	3181 SW SAM JACKSON PARK RD	PORTLAND	OR	97239	MULTNOMAH	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	4	11/29/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $346,500 )
2022	2022	OREGON HEALTH & SCIENCE UNIVERSITY	3181 SW SAM JACKSON PARK RD	PORTLAND	OR	97239	MULTNOMAH	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	4	3/29/2022	NON-COMPETING CONTINUATION	$34,650
2022	2022	OREGON HEALTH & SCIENCE UNIVERSITY	3181 SW SAM JACKSON PARK RD	PORTLAND	OR	97239	MULTNOMAH	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	4	11/19/2021	NON-COMPETING CONTINUATION	$311,850
														Subtotal = $346,500

Issue Date FY: 2021 ( Subtotal = $346,500 )
2021	2021	OREGON HEALTH & SCIENCE UNIVERSITY	3181 SW SAM JACKSON PARK RD	PORTLAND	OR	97239	MULTNOMAH	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	3	11/13/2020	NON-COMPETING CONTINUATION	$311,850
2021	2021	OREGON HEALTH & SCIENCE UNIVERSITY	3181 SW SAM JACKSON PARK RD	PORTLAND	OR	97239	MULTNOMAH	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	3	2/3/2021	NON-COMPETING CONTINUATION	$34,650
														Subtotal = $346,500

Issue Date FY: 2020 ( Subtotal = $346,500 )
2020	2020	OREGON HEALTH & SCIENCE UNIVERSITY	3181 SW SAM JACKSON PARK RD	PORTLAND	OR	97239	MULTNOMAH	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	12/19/2019	NON-COMPETING CONTINUATION	$311,850
2020	2020	OREGON HEALTH & SCIENCE UNIVERSITY	3181 SW SAM JACKSON PARK RD	PORTLAND	OR	97239	MULTNOMAH	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	2	2/10/2020	NON-COMPETING CONTINUATION	$34,650
														Subtotal = $346,500

Issue Date FY: 2019 ( Subtotal = $346,500 )
2019	2019	OREGON HEALTH & SCIENCE UNIVERSITY	3181 SW SAM JACKSON PARK RD	PORTLAND	OR	97239	MULTNOMAH	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	12/26/2018	NEW	$346,500
														Subtotal = $346,500

Grand Total All Awards = $1,386,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Magnetic Resonance (MR) Fingerprinting for Quantification of Pancreatic Tumor Microvasculature

Award Number: R01DK117459

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer